Potential for immune reconstitution through G-CSF treatment of HIV patients.
New treatment strategies for HIV/AIDS are very successful in reducing viral load. However, reconstitution of the immune system takes about one year and may be insufficient or remain incomplete. During this time the patient remains prone to opportunistic infections as a result of the complex immune dysfunction caused by the virus. Recombinant granulocyte colony-stimulating factor (G-CSF) has diverse immunomodulatory properties which may be beneficial in aiding immune reconstitution.
Von Aulock
Sonja
S
Biochemical Pharmacology, University of Konstanz, Germany.
Hartung
Thomas
T
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008231:Lymphopenia / Q000188:drug therapy / Q000276:immunology; D018448:Models, Immunological; D009000:Monocytes / Q000276:immunology; D009503:Neutropenia / Q000188:drug therapy / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D011994:Recombinant Proteins
D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor